Busy Days For Hep B Drug Development
Executive Summary
Activity in the hepatitis B field is heating up, as evidenced by recent announcements from J&J, Gilead and Dynavax.
You may also be interested in...
ContraVir Hopes To Establish Backbone For Hepatitis B Combo Therapy
Two deals have resulted in the formerly shingles-focused biotech beginning to build an HBV pipeline and look ahead to therapeutic advances similar to those seen in HIV and hepatitis C. But the New Jersey biotech will be competing with some deep-pocketed competitors in the space.
Will Dynavax’ HBV Vaccine Resubmission Make The Safety Grade?
Company says it now has enough safety data to support a new FDA filing in the first quarter of 2016, and that it expects a superiority claim for diabetics.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.